CN116077665A - 用于治疗眼科疾病和障碍的化合物 - Google Patents

用于治疗眼科疾病和障碍的化合物 Download PDF

Info

Publication number
CN116077665A
CN116077665A CN202310101659.5A CN202310101659A CN116077665A CN 116077665 A CN116077665 A CN 116077665A CN 202310101659 A CN202310101659 A CN 202310101659A CN 116077665 A CN116077665 A CN 116077665A
Authority
CN
China
Prior art keywords
compound
heterocycloalkyl
alkyl
cycloalkyl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310101659.5A
Other languages
English (en)
Chinese (zh)
Inventor
S·施佩尔
F·奥伯迈尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiola Pharmaceutical Co ltd
Original Assignee
Chiola Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiola Pharmaceutical Co ltd filed Critical Chiola Pharmaceutical Co ltd
Publication of CN116077665A publication Critical patent/CN116077665A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202310101659.5A 2014-05-08 2015-05-08 用于治疗眼科疾病和障碍的化合物 Pending CN116077665A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP14167490 2014-05-08
EP14167490.3 2014-05-08
EP14170616 2014-05-30
EP14170616.8 2014-05-30
CN201580036856.7A CN106572968A (zh) 2014-05-08 2015-05-08 用于治疗眼科疾病和障碍的化合物
PCT/EP2015/060166 WO2015169944A1 (en) 2014-05-08 2015-05-08 Compounds for treating ophthalmic diseases and disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580036856.7A Division CN106572968A (zh) 2014-05-08 2015-05-08 用于治疗眼科疾病和障碍的化合物

Publications (1)

Publication Number Publication Date
CN116077665A true CN116077665A (zh) 2023-05-09

Family

ID=53051826

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580036856.7A Pending CN106572968A (zh) 2014-05-08 2015-05-08 用于治疗眼科疾病和障碍的化合物
CN202310101659.5A Pending CN116077665A (zh) 2014-05-08 2015-05-08 用于治疗眼科疾病和障碍的化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201580036856.7A Pending CN106572968A (zh) 2014-05-08 2015-05-08 用于治疗眼科疾病和障碍的化合物

Country Status (18)

Country Link
US (3) US11730716B2 (enExample)
EP (1) EP3139914B1 (enExample)
JP (1) JP6629840B2 (enExample)
KR (1) KR102312186B1 (enExample)
CN (2) CN106572968A (enExample)
AU (1) AU2015257651B2 (enExample)
BR (1) BR112016025997A8 (enExample)
CA (1) CA2947067C (enExample)
CL (1) CL2016002812A1 (enExample)
ES (1) ES2960598T3 (enExample)
HK (1) HK1231417A1 (enExample)
IL (1) IL248732B (enExample)
MX (1) MX378707B (enExample)
NZ (1) NZ725574A (enExample)
PL (1) PL3139914T3 (enExample)
SG (1) SG11201608835VA (enExample)
WO (1) WO2015169944A1 (enExample)
ZA (1) ZA201607260B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
CN106572968A (zh) * 2014-05-08 2017-04-19 帕诺泰斯制药有限公司 用于治疗眼科疾病和障碍的化合物
KR20170091157A (ko) 2014-12-23 2017-08-08 4디 파마 리서치 리미티드 피린 폴리펩티드 및 면역 조정
KR102523805B1 (ko) 2014-12-23 2023-04-20 4디 파마 리서치 리미티드 면역 조정
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
RS59038B1 (sr) 2015-06-15 2019-08-30 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
JP6426264B2 (ja) 2015-06-15 2018-11-21 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
PL3240554T3 (pl) 2015-06-15 2020-02-28 4D Pharma Research Limited Blautia stercosis i wexlerae do stosowania w leczeniu chorób zapalnych i autoimmunologicznych
CA3005781C (en) 2015-11-20 2019-01-22 4D Pharma Research Limited Compositions comprising bacterial strains
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) * 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
KR20180102105A (ko) * 2015-12-30 2018-09-14 아지오스 파마슈티컬스 아이엔씨. 돌연변이체 이소시트레이트 데히드로게나제를 포함하고 있는 종양의 치료
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
HK1246670B (en) 2016-03-04 2020-05-15 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
SMT202100553T1 (it) 2017-04-24 2021-11-12 Aurigene Discovery Tech Ltd Metodi d'uso per derivati benzotriazolici trisostituiti come inibitori di diidroorotato ossigenasi
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
EP3630136B1 (en) 2017-05-22 2021-04-21 4D Pharma Research Limited Compositions comprising bacterial strains
MA41708A (fr) 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
EP3600363B1 (en) 2017-06-14 2020-12-02 4D Pharma Research Limited Compositions comprising bacterial strains
WO2018229188A1 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
HUE052258T2 (hu) 2017-06-14 2021-04-28 4D Pharma Res Ltd Megasphaera nemzetségbe tartozó baktériumtörzset tartalmazó készítmény, és alkalmazása
US20200121652A1 (en) * 2017-06-16 2020-04-23 The Doshisha Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent
EP3639854A4 (en) 2017-06-16 2021-03-03 The Doshisha MTOR INHIBITIVE MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF OPHTHALMIC SYMPTOMS, DISORDERS, OR DISEASES AND USE THEREOF
US11717512B2 (en) 2018-02-20 2023-08-08 Servier Pharmaceuticals Llc Methods of use for trisubstituted benzotriazole derivatives
EP3761960B1 (en) 2018-03-09 2023-11-22 Kiora Pharmaceuticals GmbH Ophthalmic formulation
KR102764121B1 (ko) * 2018-03-16 2025-02-05 이뮤닉 아게 항-염증제, 면역조절제 및 항-증식제로서의 신규한 칼슘 염 다형체
US10889548B2 (en) 2018-03-26 2021-01-12 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
US20210315880A1 (en) 2020-03-20 2021-10-14 Clear Creek Bio, Inc. Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
EP4138779A4 (en) * 2020-04-21 2024-05-22 University of Massachusetts Methods and compositions for treatment of age-related macular degeneration
CN111638341A (zh) * 2020-07-01 2020-09-08 山东凯歌智能机器有限公司 一种检测小细胞肺癌患者外周血循环肿瘤细胞pd-l1基因突变的试剂盒及检测方法
WO2022081095A1 (en) * 2020-10-15 2022-04-21 Aslan Pharmaceuticals Pte. Ltd. Treatment of autoimmune diseases with a dihydroorotate hehydrogenase (dhodh) inhibitor
BR112023020806A2 (pt) 2021-04-09 2023-12-12 Immunic Ag Inibidores de dhodh deuterados
UY40087A (es) 2021-12-23 2023-06-30 Immunic Ag Inhibidores de DHODH que contienen un bioisóstero de ácido carboxílico.
IL315335A (en) * 2022-03-01 2024-10-01 Kiora Pharmaceuticals Gmbh salts of dehydrogenase inhibitor (DHOD)
KR20250007508A (ko) 2022-03-09 2025-01-14 키오라 파마슈티칼스 게엠베하 디하이드로오로테이트 탈수소효소(dhod) 억제제의 다형체
TW202506107A (zh) 2023-06-28 2025-02-16 德商埃慕尼克股份公司 雜芳族dhodh抑制劑

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056747A1 (en) * 2002-12-23 2004-07-08 4Sc Ag Dhodh-inhibitors and method for their identification
US20040176458A1 (en) * 2002-12-23 2004-09-09 4 Sc Ag Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61103836A (ja) 1984-10-24 1986-05-22 Green Cross Corp:The フイブロネクチン製剤
DD297328A5 (de) * 1989-08-18 1992-01-09 �������@���������k���Kk�� 5-methyl-isoxalol-4-carbonsaeureanilide und 2 hydroxyethyliden-cyanoessigsaeureanilide zur behandlung von augenerkrankungen
WO1997039769A1 (en) 1996-04-19 1997-10-30 R-Tech Ueno, Ltd. Drug composition comprising albumin as active ingredient
HUP9701554D0 (en) 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
WO2003006424A1 (en) 2001-07-10 2003-01-23 4Sc Ag Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
AU2003301347A1 (en) * 2002-10-17 2004-05-04 Control Delivery Systems, Inc. Methods for monitoring treatment of disease
CN1732163B (zh) * 2002-12-23 2012-07-18 4Sc股份公司 作为抗炎和免疫调节及抗增殖试剂的芳香化合物
US7365094B2 (en) 2002-12-23 2008-04-29 4Sc Ag Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
WO2005095397A1 (en) 2004-03-11 2005-10-13 Actelion Pharmaceuticals Ltd Tetrahydropyridoindole derivatives
WO2006022442A1 (ja) * 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
JP2006089485A (ja) * 2004-08-24 2006-04-06 Santen Pharmaceut Co Ltd ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
WO2007038687A2 (en) * 2005-09-27 2007-04-05 Aciont, Inc. Ocular administration of immunosuppressive agents
ES2319596B1 (es) * 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
JP2009270356A (ja) 2008-05-08 2009-11-19 Yoshinobu Hayashi アスベスト含有被覆層剥ぎ取り物の処理方法
TWI530286B (zh) 2009-05-04 2016-04-21 帕納特斯製藥格斯有限公司 作為抑制病毒化合物之抗發炎劑
US20110021465A1 (en) * 2009-07-23 2011-01-27 U.S. Nutraceuticals, Llc D/B/A Valensa International Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
WO2013036309A2 (en) * 2011-06-10 2013-03-14 Wong Vernon G Sustained release formulations for delivery of proteins to the eye and methods of preparing same
KR102265277B1 (ko) 2014-04-11 2021-06-16 판옵테스 파르마 게스.엠.베.하. 바이러스 억제 화합물로서의 항-염증제
CN106572968A (zh) * 2014-05-08 2017-04-19 帕诺泰斯制药有限公司 用于治疗眼科疾病和障碍的化合物
KR20180102105A (ko) 2015-12-30 2018-09-14 아지오스 파마슈티컬스 아이엔씨. 돌연변이체 이소시트레이트 데히드로게나제를 포함하고 있는 종양의 치료
EP3761960B1 (en) 2018-03-09 2023-11-22 Kiora Pharmaceuticals GmbH Ophthalmic formulation
BR112023020806A2 (pt) 2021-04-09 2023-12-12 Immunic Ag Inibidores de dhodh deuterados
IL315335A (en) 2022-03-01 2024-10-01 Kiora Pharmaceuticals Gmbh salts of dehydrogenase inhibitor (DHOD)
KR20250007508A (ko) 2022-03-09 2025-01-14 키오라 파마슈티칼스 게엠베하 디하이드로오로테이트 탈수소효소(dhod) 억제제의 다형체

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056747A1 (en) * 2002-12-23 2004-07-08 4Sc Ag Dhodh-inhibitors and method for their identification
US20040176458A1 (en) * 2002-12-23 2004-09-09 4 Sc Ag Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PEYMAN GA等: "Intravitreal injection of therapeutic agents", 《RETINA》, vol. 29, no. 7, 31 August 2009 (2009-08-31), pages 883 *

Also Published As

Publication number Publication date
SG11201608835VA (en) 2016-11-29
CA2947067A1 (en) 2015-11-12
PL3139914T3 (pl) 2023-11-27
JP6629840B2 (ja) 2020-01-15
JP2017514917A (ja) 2017-06-08
US12364680B2 (en) 2025-07-22
EP3139914C0 (en) 2023-07-26
CN106572968A (zh) 2017-04-19
CA2947067C (en) 2023-02-14
WO2015169944A1 (en) 2015-11-12
KR20160147023A (ko) 2016-12-21
US20250381167A1 (en) 2025-12-18
CL2016002812A1 (es) 2017-03-17
US20230285355A1 (en) 2023-09-14
EP3139914B1 (en) 2023-07-26
AU2015257651B2 (en) 2020-01-23
US20170071904A1 (en) 2017-03-16
MX378707B (es) 2025-03-10
BR112016025997A2 (pt) 2017-08-15
MX2016014634A (es) 2017-04-10
NZ725574A (en) 2022-08-26
AU2015257651A1 (en) 2016-11-10
ES2960598T3 (es) 2024-03-05
US11730716B2 (en) 2023-08-22
IL248732A0 (en) 2017-01-31
ZA201607260B (en) 2018-05-30
HK1231417A1 (zh) 2017-12-22
EP3139914A1 (en) 2017-03-15
KR102312186B1 (ko) 2021-10-14
IL248732B (en) 2019-07-31
BR112016025997A8 (pt) 2021-07-06

Similar Documents

Publication Publication Date Title
US12364680B2 (en) Compounds for treating ophthalmic diseases and disorders
Schopf et al. Topical ocular drug delivery to the back of the eye by mucus-penetrating particles
CN103037857B (zh) 用于治疗/预防眼部炎性疾病的化合物
BRPI0915981A2 (pt) método para tratar a degeneração macular atrófica relacionada à idade
CN119656170A (zh) 使用尼达尼布来治疗具有异常新生血管形成的眼病的组合物和方法
CN109996814B (zh) 多激酶抑制剂及在眼部纤维化中的用途
JP2020055862A (ja) 持続的薬物送達インプラントによる眼の状態の治療の方法
Reijerkerk et al. Systemic treatment with glutathione PEGylated liposomal methylprednisolone (2B3-201) improves therapeutic efficacy in a model of ocular inflammation
JP2024534570A (ja) 眼炎症性疾患を処置する方法
JP7470791B2 (ja) 眼疾患の予防または治療用点眼組成物
US20240366565A1 (en) Use of Verteporfin to Modulate Wound Healing After an Ocular Surgical Procedure or Ocular Injury
WO2020009248A1 (ja) 眼組織の線維化抑制用組成物
JP2011144111A (ja) 軸性近視の予防または治療剤
CN116515827B (zh) 用于治疗年龄相关性黄斑变性的活性成分、药物组合物和应用
MX2011005586A (es) Composiciones de soluciones oculares topicas para suministrar concentraciones efectivas de agente activo al segmento posterior del ojo.
Koike et al. Trabeculotomy in a Behcet’s disease patient one week after infliximab administration
CN117355292A (zh) 用于预防或治疗眼病的抑制n-氧代吡啶化合物出现的眼科组合物
Sahoo et al. Mucoadhesive nanopolymers for posterior segment drug delivery
FR2963238A1 (fr) Derives de 15-desoxyspergualine pour le traitement et/ou la prevention des maladies inflammatoires oculaires

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40092417

Country of ref document: HK